Sarepta Therapeutics announces hold to clinical study SRP-5051-201 (MOMENTUM) in the US
Sarepta has announced that the United States Food and Drug Administration (FDA) has placed a clinical hold on SRP-5051 (vesleteplirsen) in the United States following a serious adverse event of hypomagnesemia (low magnesium). To date, there has been no action by the EMA or MHRA to hold the trial in the UK.
If your child is a participant in the UK trial, please contact your trial site. If you are not on the Momentum clinical trial and have any questions then please contact Duchenne UK; [email protected]
For more information, please read the Community letter here.
Published on 24 June 2022Share this article Categories DMD research